Canabiotic present a unique formula CBG oil. Usually CBG exist in plant in lower concentrations. It is one of the most expensive cannabinoids to produce. Canabiotic managed to find certified in EU Cannabis Sativa L strains, concentrating high amount of CBG with nearly 0% THC. Canabiotic Canabiotic is a premium quality 100% natural, full-spectrum extract. It contains all naturally occurring cannabinoids vitamins, minerals, terpenes, chlorophyll, flavonoids and polyphenols. The product does not contain psychoactive substances. THC <0.2%. No filtration, no purification, no cleaning, no solvents, no isolated substances, no synthetic additives were used in the production. It is plant extract as it grows.
What is CBG?
Cannabigerol, or CBG, is a non-psychoactive, non-toxic cannabinoid typically most abundant in low-THC and high-CBD cannabis strains. CBG works to fight inflammation, pain, nausea and works to slow the proliferation of cancer cells. Research has shown it also significantly reduces intraocular eye pressure caused by glaucoma. CBG will be beneficial treating conditions such as inflammatory bowel disease, Crohn’s disease, neurodegenerative diseases including Huntington’s Disease, anxiety, panic attacks, chronic pain and cancer.
CBG for Gastrointestinal Health
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a multifactorial, chronic immune-mediated disease of the GI tract that results from a complex interaction between environmental, genetic and epigenetic risk factors that cause an inappropriate mucosal immune response leading to intestinal inflammation.
Numerous reports and meta-analyses have identified an important role for cannabinoids in the control of GI functions in health and disease states. In conclusion the non-psychotropic Phytocannabinoid CBG, may exert beneficial actions with therapeutic potential via cannabinoid receptors CBG attenuated murine colitis, reduced nitric oxide production in macrophages (effect being modulated by the CB2 receptor) and reduced ROS (reactive oxygen species) formation in intestinal epithelial cells. CBG could be considered for clinical experimentation in IBD patients.
Available experimental data show that the ECS is implicated in the control of motility, secretion, epithelial barrier function and viscerosensitivity, being a key component in the maintenance of GI homeostasis and a significant player in several pathophysiological states implicating a neuro-immuno-endocrine dysregulation of the GI tract.
Main references:
https://www.sciencedirect.com/science/article/abs/pii/S0006295213000543?via%3Dihub
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246936/
CBG Role in Gastrointestinal Cancer
Observations support the potential role of cannabinoids regulating cancer progression. The effects of cannabinoids on intestinal carcinogenesis have been evaluated in CRC epithelial cells, in experimental models of colon cancer and on gastric cancer cell lines. Overall, cannabinoids might exert protective effects on carcinogenesis directly, through activation of cannabinoid receptors, or indirectly, through elevation of endocannabinoid levels via inhibition of metabolizing enzymes (particularly FAAH). In any case, activation of cannabinoid receptors is associated with anti-proliferative effects, the promotion of apoptosis, the inhibition of tumor cells migration and/or the inhibition of angiogenesis.
Main references:
https://pubmed.ncbi.nlm.nih.gov/29482741/
https://pubmed.ncbi.nlm.nih.gov/31413731/
https://pubmed.ncbi.nlm.nih.gov/18676872/
https://pubmed.ncbi.nlm.nih.gov/22555283/
CBG may reduce the intraocular pressure of those with glaucoma
As a result of Colasanti’s experiments, the study concluded that CBG “may have therapeutic potential for the treatment of glaucoma.” A 2018 paper looked into the topic further and found that CBG may reduce the intraocular pressure of those with glaucoma “due to the activation of GPR18, which has been localized to the ciliary epithelium and iris.” That finding was partly based off research that was published in 2011 that looked at the pharmacological properties of an analog of CBG, CBG-DMH. The results of that study, which were published in the Journal of Ocular Pharmacology and Therapeutics mirrored the attenuating effects that CBG and its derivatives have on intraocular pressure. Afterall, CBG and its derivatives seem to have the “potential for further investigation as novel ocular hypotensive cannabinoids devoid of CB(1)R-mediated side-effects.”
Main references:
https://journalofcannabinoidmedicine.com/cbg-may-be-a-good-for-eye-health/
CBG and neurodegeneration
The anti-oxidant and anti-inflammatory actions of CBG are particularly interesting taking into account that both inflammation and oxidative stress play pivotal roles in neurodegeneration including Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. Indeed, both these processes lead to neuronal cell death, then triggering and amplifying degeneration. We observed with all doses an increase in cell viability compared to the control, even if the difference was not statistically significant. Control NSC-34 motor neurons and cells treated with CBG alone evidenced the absence of oxidative marker expression. In particular, CBG restored cell anti-oxidant defense, and educed oxidative stress and inflammatory markers. On the bases of these results, thanks to its neuroprotective effects, we encourage the use of CBG against neurodegeneration and in those pathological conditions where neuroinflammation and oxidative stress play a main role.
Main reference:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073490/
CBG mood-altering benefits
ACBG help regulate mood thanks to its ability to boost anandamide, the body’s native “bliss” molecule, as well as act as a GABA reuptake inhibitor. CBG is also a potent neuroprotectant and is currently being evaluated for its ability to combat ailments like.
Cannabinoids in the Management of Difficult to Treat Pain
Cannabinoid compounds may be more effective in the context of chronic neuropathic pain than for the management of acute pain.
Main references:
https://pubmed.ncbi.nlm.nih.gov/29513392/
https://pubmed.ncbi.nlm.nih.gov/18728714/
CBG and CBC anticancer properties
A new series of tests conducted in Israel have shown that both CBC and CBG exhibit anti-tumour properties on cancer cells. CBC is an additional non-psychoactive cannabinoid and is one of the naturally occurring phyto-cannabinoids, bearing a host of potential positive therapeutic qualities and may promote antimicrobial, anti‐inflammatory, analgesic, and neurogenesis activity. CBG were both shown to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids. CBC and CBG, as neutral cannabinoids, were both found to have a TPSA value which allows the cannabinoid molecule to penetrate a cancer cell’s membrane. A report has assessed the anticancer effects of CBG on colon carcinogenesis. Cannabigerol inhibited the growth of CRC cells (Caco-2 and HTC 116) mainly via a pro-apoptotic mechanism, associated with ROS overproduction, and hindered the development and the growth of colon carcinogenesis in vivo.
Main references:
https://www.healtheuropa.eu/cannabinoids-cbc-and-cbg-exhibit-anti-tumour-properties-on-cancer-cells/97058/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246936/
